Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma 
Welcome,         Profile    Billing    Logout  
 29 Diseases   4 Trials   4 Trials   103 News 


12»
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Enrollment closed:  The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) -  Oct 3, 2024   
    P2,  N=12, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  vosilasarm (EP0062) / Ellipses Pharma, Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Journal:  Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use. (Pubmed Central) -  Aug 15, 2024   
    Cessation of these supplements led to full resolution of symptoms including normalization of hypogonadotropic hypogonadism. This case highlights the need for clinicians to consider commercially available performance-enhancing supplements as potential sources of PEDs and exogenous steroid hormones that can have adverse clinical consequences.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Journal:  GHSR signalling in perinatal phases is involved in liver metabolism at puberty. (Pubmed Central) -  Aug 12, 2024   
    (ii) Postnatal modulation of GHSR with LEAP2[1-14] or MK677...The observed results suggests that perinatal LEAP2 exposure can modulate liver metabolism and systemic glucose homeostasis. In addition, these results, although not expressive, may just be the beginning of the metabolic imbalance that will occur in adulthood.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Trial completion date, Trial primary completion date:  The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) -  Jul 31, 2024   
    P2,  N=12, Recruiting, 
    In addition, these results, although not expressive, may just be the beginning of the metabolic imbalance that will occur in adulthood. Trial completion date: Jun 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Feb 2025
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Trial completion date, Trial primary completion date:  Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) (clinicaltrials.gov) -  Feb 20, 2024   
    P2,  N=80, Active, not recruiting, 
    Trial completion date: Jun 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Feb 2025 Trial completion date: Apr 2025 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (clinicaltrials.gov) -  Feb 2, 2024   
    P2,  N=18, Active, not recruiting, 
    Trial completion date: Nov 2028 --> Apr 2028 Enrolling by invitation --> Active, not recruiting | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Jan 2024 --> Feb 2025
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Trial primary completion date:  PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (clinicaltrials.gov) -  Oct 4, 2023   
    P2,  N=24, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Jan 2024 --> Feb 2025 Trial primary completion date: Jun 2023 --> Apr 2030
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Journal:  Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration. (Pubmed Central) -  Mar 15, 2023   
    Wash criteria to differentiate between internal incorporation (via bloodstream) and external deposition (via sweat and sebum) was also assessed and indicated internal incorporation for the samples collected at later time points (? 52 days) and a combination of internal incorporation and external deposition for hair samples collected at the earlier time point (2 days).
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Preclinical, Journal:  Ghrelin receptor agonist MK0677 and overnight fasting do not rescue deficient fear extinction in 129S1/SvImJ mice. (Pubmed Central) -  Feb 27, 2023   
    In summary, our findings are in contrast to several studies reporting beneficial effects of GHSR agonism and overnight fasting on fear- and anxiety-related behaviors in rodents. Rather, our data agree with accumulating evidence of divergent behavioral effects of ghrelin system activation and underscore the hypothesis that potential benefits of targeting the ghrelin system in fear extinction may be dependent on factors (e.g., previous stress exposure) that are not yet fully understood.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Enrollment open:  The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) -  Sep 28, 2022   
    P2,  N=12, Recruiting, 
    Rather, our data agree with accumulating evidence of divergent behavioral effects of ghrelin system activation and underscore the hypothesis that potential benefits of targeting the ghrelin system in fear extinction may be dependent on factors (e.g., previous stress exposure) that are not yet fully understood. Not yet recruiting --> Recruiting
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Journal:  Binding Domain Characterization of Growth Hormone Secretagogue Receptor. (Pubmed Central) -  Aug 13, 2022   
    We used radiolabeled ligand-binding assay and growth hormone release assay to assess the binding and functional characteristics of GHS-R to synthetic agonists MK-0677 and GHS-25, as well as to endogenous peptide ligand ghrelin...The ligand-binding pocket of human GHS-R is mainly defined by interactive residues in TM6 and the adjacent region of the receptor. This novel finding in GHS-R binding domains advances the structural/ functional understanding of GHS-R, which will help to select/design better GHS-R agonists/ antagonists for future therapeutic applications.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Enrollment open:  Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) (clinicaltrials.gov) -  Mar 11, 2022   
    P2,  N=20, Enrolling by invitation, 
    LUM-201 elicits greater GH responses than standard stimuli in subjects with higher peak GH in response to conventional testing and is potentially an orally administered treatment alternative to injectable rhGH in a subset of patients with adequate responses to an acute dose of LUM-201. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Trial completion date, Trial primary completion date:  PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (clinicaltrials.gov) -  Jan 24, 2022   
    P2,  N=24, Recruiting, 
    The reported data help in the speedy detection of the growth hormone secretagogue ibutamoren and reveal its illegal use in competitive sports. Trial completion date: Nov 2022 --> Jul 2023 | Trial primary completion date: Oct 2022 --> Jun 2023
  • ||||||||||  Livial (tibolone) / Merck (MSD), Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Preclinical, Journal:  An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. (Pubmed Central) -  Dec 16, 2021   
    The variety of tests employed should produce a comprehensive data set to better understand how a compound under investigation may impact the steroid profile. While our data set may allow an estimate of whether or not a substance will have an impact on the overall steroid metabolism, predicting which parameter in particular may be influenced remains difficult.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Trial completion date, Trial primary completion date:  Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) (clinicaltrials.gov) -  Oct 28, 2021   
    P2,  N=80, Recruiting, 
    While our data set may allow an estimate of whether or not a substance will have an impact on the overall steroid metabolism, predicting which parameter in particular may be influenced remains difficult. Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Sep 2023
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Phase classification, Trial completion date, Trial primary completion date:  Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) (clinicaltrials.gov) -  Sep 28, 2021   
    P2,  N=80, Recruiting, 
    This rapid and accurate LC-MS/MS method can therefore be successfully applied to screen and identify SARMs for the continuous control and supervision of dietary supplements. Phase classification: P2b --> P2 | Trial completion date: Mar 2022 --> Oct 2023 | Trial primary completion date: Dec 2021 --> Mar 2023
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Journal:  Brain and renal GHS-R1a underexpression is associated with changes in renal function and hemodynamics during neurogenic hypertension. (Pubmed Central) -  Jul 14, 2021   
    First, we assessed the effect of systemically injected vehicle, ghrelin, GHS-R1a antagonist PF04628935, ghrelin plus PF04628935 or GHS-R1a synthetic agonist MK-677 in WT and SHR rats housed in metabolic cages (24 h)...GHS-R1a protein levels were decreased in the kidney and brain areas of SHR when compared to WT. Therefore, GHS-R1a role in the control of renal function and hemodynamics during neurogenic hypertension seem to be different, and this may be related to brain GHS-R1a downregulation.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Enrollment open:  PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (clinicaltrials.gov) -  Jun 30, 2021   
    P2,  N=24, Recruiting, 
    Therefore, GHS-R1a role in the control of renal function and hemodynamics during neurogenic hypertension seem to be different, and this may be related to brain GHS-R1a downregulation. Not yet recruiting --> Recruiting
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    [VIRTUAL] LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1617;    
    The difference is greatest among patients with higher baseline values of IGF-I and higher GH responses to standard stimuli. The synergistic actions of LUM-201 on the physiological mechanisms regulating GH release explain why GH responses are greater in response to LUM-201 compared to traditional tests used to diagnose PGHD.
  • ||||||||||  Oratrope (ibutamoren) / Merck (MSD), Lumos Pharma
    Preclinical, Journal:  Effects of ghrelin receptor activation on forebrain dopamine release, conditioned fear and fear extinction in C57BL/6J mice. (Pubmed Central) -  Dec 17, 2020   
    Our data show that systemic administration of the ghrelin receptor agonist MK0677, in a dose that induces food intake, has no significant effect on auditory fear processing and does not significantly affect dopamine release in the nucleus accumbens of male C57BL/6J mice...However, we found that neither overnight food deprivation nor genetic ablation of the ghrelin receptor had a significant effect on auditory fear extinction. We conclude that the effects of manipulation of the ghrelin system on fear processing are subject to boundary conditions that remain poorly understood.